Label: PENICILLIN V POTASSIUM tablet

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated August 20, 2014

If you are a consumer or patient please visit this version.

  • Indications and Usage

    ​To reduce the development of drug-resistant bacteria and maintain the effectiveness of Penicillin V Potassium Tablets, Penicillin V Potassium for Oral Solution and other antibacterial drugs, Penicillin V Potassium Tablets, and Penicillin V Potassium for Oral Solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy.

    In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

    Penicillin V Potassium Tablets, USP and Penicillin V Potassium for Oral Solution, USP, are indicated in the treatment of mild to moderately severe infections due to penicillin G sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response.

    NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage.

    Indicated surgical procedures should be performed.

    The following Infections will usually respond to adequate dosage of Penicillin V:

    Streptococcal infections (without bacteremia): Mild to moderate infections of the upper respiratory tract, scarlet fever and mild erysipelas.

    NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus) are resistant.

    Pneumococcal infections: Mild to moderately severe infections of the respiratory tract.

    Staphylococcal infections - penicillin G sensitive: Mild infections of the skin and soft tissues.

    NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections.

    Fusospirochetosis (Vincent's gingivitis and pharyngitis): Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin.

    NOTE: Necessary dental care should be accomplished in infections involving the gum tissue.

    Medical conditions in which oral penicillin therapy is indicated as prophylaxis:

    For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions.

    Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract.1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g. those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha haemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents, other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen.

    NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association.

    THE MANUFACTURER'S COMPLETE DRUG INFORMATION CAN BE VIEWED ON THE FDA SITE HERE;


    http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d6417642-66c5-48b5-86bf-ffb87c4250ac

  • Contraindications

    A previous hypersensitivity reaction to any penicillin is a contraindication.

  • Warnings

    SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (ANAPHYLACTIC) REACTIONS HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY. THESE REACTIONS ARE MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY AND/OR A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS. THERE HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY WHO HAVE EXPERIENCED SEVERE REACTIONS WHEN TREATED WITH CEPHALOSPORINS. BEFORE INITIATING THERAPY WITH PENICILLIN V POTASSIUM, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTION TO PENICILLINS, CEPHALOSPORINS, OR OTHER ALLERGENS. IF AN ALLERGIC REACTION OCCURS, PENICILLIN V POTASSIUM SHOULD BE DISCONTINUED AND APPROPRIATE THERAPY INSTITUTED. SERIOUS ANAPHYLACTOID REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED.

    Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Penicillin V Potassium Tablets and Penicillin V Potassium for Oral Solution, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

    C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may cause colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

    If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

  • Precautions

    General

    Penicillin should be used with caution in individuals with histories of significant allergies and/or asthma.

    Prescribing Penicillin V Potassium Tablets and Penicillin V Potassium for Oral Solution in the absence of a proven or strongly suspected bacterial infection of a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

    The oral route of administration should not be relied upon in patients with severe illness, or with nausea, vomiting, gastric dilatation, cardiospasm or intestinal hypermotility.

    Occasionally patients will not absorb therapeutic amounts of orally administered penicillin.

    In streptococcal infections, therapy must be sufficient to eliminate the organism (ten-day minimum): otherwise the sequelae of streptococcal disease may occur. Cultures should be taken following completion of treatment to determine whether streptococci have been eradicated.

    Prolonged use of antibiotics may promote the overgrowth of nonsusceptible organisms, including fungi. Should superinfection occur, appropriate measures should be taken.

    Oral Solutions contain aspartame. Phenylketonurics: Both the 125 mg and 250 mg Oral Solutions contain phenylalanine 4.5 mg per 5 mL.

    Information for Patients

    Patients should be counseled that antibacterial drugs, including Penicillin V Potassium Tablets and Penicillin V Potassium for Oral Solution should only be used to treat bacterial infections. They do not treat viral infections (e.g. the common cold).

    When Penicillin V Potassium Tablets or Penicillin V Potassium Oral Solution are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may:

    (i) Decrease the effectiveness of the immediate treatment, and

    (ii) Increase the likelihood that bacteria will develop resistance and will not be treatable by the antibacterial drug product or other antibacterial drugs in the future.

    Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

  • Adverse Reactions

    Although the incidence of reactions to oral penicillins has been reported with much less frequency than following parenteral therapy, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been reported with oral penicillin.

    The most common reactions to oral penicillin are nausea, vomiting, epigastric distress, diarrhea, and black hairy tongue. The hypersensitivity reactions reported are skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum sickness-like reactions, laryngeal edema and anaphylaxis.

    Fever and eosinophilia may frequently be the only reaction observed. Hemolytic anemia, leukopenia, thrombocytopenia, neuropathy and nephropathy are infrequent reactions and usually associated with high doses of parenteral penicillin.

  • Dosage and Administration

    The dosage of penicillin V potassium tablets and penicillin V potassium for oral solution should be determined according to the sensitivity of the causative microorganisms and the severity of the infection, and adjusted to the clinical response of the patient.

    The usual dosage recommendations for adults and children 12 years and over are as follows:

    Streptococcal infections - mild to moderately severe - of the upper respiratory tract and including scarlet fever and erysipelas: 125 mg to 250 mg (200,000 to 400,000 units) every 6 to 8 hours for 10 days.

    Pneumococcal infections - mild to moderately severe - of the respiratory tract, including otitis media: 250 mg to 500 mg (400,000 to 800,000 units) every 6 hours until the patient has been afebrile for at least 2 days.

    Staphylococcal infections - mild infections of skin and soft tissue (culture and sensitivity tests should be performed): 250 mg to 500 mg (400,000 to 800,000 units) every 6 to 8 hours.

    Fusospirochetosis (Vincent's infection) of the oropharynx. Mild to moderately severe infections: 250 mg to 500 mg (400,000 to 800,000 units) every 6 to 8 hours.

    For the prevention of recurrence following rheumatic fever and/or chorea: 125 mg to 250 mg (200,000 to 400,000 units) twice daily on a continuing basis.

    For prophylaxis against bacterial endocarditis1 in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when undergoing dental procedures or surgical procedures of the upper respiratory tract: 2 grams of penicillin V (1 gram for children under 60 lbs) 1 hour before the procedure, and then 1 gram (500 mg for children under 60 lbs) 6 hours later.

  • Label Display

    NDC: 51655-011-52

    Penicillin V Potassium 500MG

    30 Tablets

    Lot:                  Exp:                Rx Only

    Store at 20C to 25C (68-77F)

    Keep out of reach of children.  Dosage: See package insert

    Manufactured by: Stada Ireland Limited

    Manufacture Address: Clonmel, Ireland

    Manufacture NDC: 67253-201-50      Mfg Lot:

    Distributed by Northwind Pharmaceuticals, Indianapolis, IN 46256

    51655-011-52

    NDC: 51655-011-20

    Penicillin V Potassium 500MG

    20 Tablets

    Lot: Exp: Rx Only

    Store at 20C to 25C (68-77F)

    Keep out of reach of children. Dosage: See package insert

    Manufactured by: Stada Ireland Limited

    Manufacture Address: Clonmel, Ireland

    Manufacture NDC: 67253-201-50 Mfg Lot:

    Distributed by Northwind Pharmaceuticals, Indianapolis, IN 46256

    51655-011-20

    NDC: 51655-011-03

    Penicillin V Potassium 500MG

    3 Tablets

    Lot: Exp: Rx Only

    Store at 20C to 25C (68-77F)

    Keep out of reach of children. Dosage: See package insert

    Manufactured by: Stada Ireland Limited

    Manufacture Address: Clonmel, Ireland

    Manufacture NDC: 67253-201-50 Mfg Lot:

    Distributed by Northwind Pharmaceuticals, Indianapolis, IN 46256

    51655-011-03

    NDC: 51655-011-51

    Penicillin V Potassium 500MG

    40Tablets

    Lot:          Exp:                Rx Only

    Store at 20C to 25C (68-77F)

    Keep out of reach of children. Dosage: See package insert

    Manufactured by: Stada Ireland Limited

    Manufacture Address: Clonmel, Ireland

    Manufacture NDC: 67253-201-11 Mfg Lot:

    Distributed by Northwind Pharmaceuticals, Indianapolis, IN 46256

    51655-011-51

  • INGREDIENTS AND APPEARANCE
    PENICILLIN V POTASSIUM 
    penicillin v potassium tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:51655-011(NDC:67253-201)
    Route of AdministrationOral
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    PENICILLIN V POTASSIUM (UNII: 146T0TU1JB) (PENICILLIN V - UNII:Z61I075U2W) PENICILLIN V500 mg
    Product Characteristics
    ColorwhiteScoreno score
    ShapeOVALSize16mm
    FlavorImprint Code S21
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:51655-011-5230 in 1 BOTTLE, DISPENSING
    2NDC:51655-011-2020 in 1 BOTTLE, DISPENSING
    3NDC:51655-011-033 in 1 BOTTLE, DISPENSING
    4NDC:51655-011-5140 in 1 BOTTLE, DISPENSING
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA06293506/01/2014
    Labeler - Northwind Pharmaceuticals (036986393)
    Registrant - Northwind Pharmaceuticals (036986393)
    Establishment
    NameAddressID/FEIBusiness Operations
    EPM Packaging079124340repack(51655-011)